β-内酰胺类非即刻皮肤不良反应后的交叉反应:参考中心经验
通过斑贴试验和皮内试验发现,在18例阿莫西林疑似阳性患者中,55.6%与一种或多种其他β-内酰胺类交叉反应,但未见与氨曲南或碳青霉烯类交叉反应。结论提示需广泛过敏学检查以评估交叉反应。
要点
- 疑似β-内酰胺类非即刻皮肤不良反应后,应进行斑贴试验和皮内试验以确认诊断。
- 阿莫西林疑似患者中交叉反应常见,尤其与其他青霉素类,建议停用整个青霉素家族。
- 未观察到与氨曲南或碳青霉烯类的交叉反应,但仍需测试这些药物。
核心结论
- β-内酰胺类非即刻皮肤不良反应后交叉反应常见,需广泛过敏学检查确认诊断和评估交叉反应。
- 青霉素类之间交叉反应频繁,建议停用整个青霉素家族并测试头孢菌素、氨曲南和碳青霉烯类。
研究设计与样本
- 回顾性单中心研究,纳入2010–2018年间连续就诊的56例疑似β-内酰胺类非即刻皮肤不良反应患者。
- 对至少三种青霉素亚类以及氨基头孢菌素和非氨基头孢菌素(至少一种氨基头孢菌素)进行皮肤试验(斑贴试验和皮内试验)。
- 对试验阳性患者调查亚类间交叉反应。
主要发现
- 18例阿莫西林疑似阳性患者中,10例(55.6%)与一种或多种其他β-内酰胺类交叉反应:9例(50%)与另一种青霉素,3例(16.5%)与非氨基头孢菌素。
- 未观察到阿莫西林或头孢菌素疑似患者与氨曲南或碳青霉烯类交叉反应。
- 皮内试验仅显示一次交叉反应。
关键数值与推荐
- 交叉反应定义:试验阳性患者对另一种β-内酰胺类皮肤试验阳性。
- 阿莫西林疑似阳性患者中交叉反应率:与其他青霉素50%,与非氨基头孢菌素16.5%。
临床怎么用
- 对疑似β-内酰胺类非即刻皮肤不良反应患者,应进行广泛过敏学检查,包括斑贴试验和皮内试验。
- 若阿莫西林过敏确认,建议停用所有青霉素类药物,并测试头孢菌素、氨曲南和碳青霉烯类以评估交叉反应。
局限性
- 回顾性单中心研究,样本量较小(56例)。
- 仅纳入就诊于参考中心的患者,可能存在选择偏倚。
- 皮内试验交叉反应仅显示一次,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cross-reactivity among beta-lactam antibiotics (BL) is essentially reported in immediate hypersensitivity. OBJECTIVES: To evaluate cross-reactivity beyond BLs in patients with non-immediate cutaneous adverse drug reaction (non-immediate CADR) managed in a dermatology reference centre of toxic bullous and severe CADRs. PATIENTS/MATERIALS/METHODS: We conducted a retrospective single-centre study in consecutive patients consulting between 2010 and 2018 with an active BL-suspected non-immediate CADR and explored by cutaneous tests [patch tests (PT) and intradermal tests (P-IDR)] for at least three penicillin's subclasses and amino- and non-amino-cephalosporins (at least one aminocephalosporin). Cross-reactivity among subclasses was investigated for patients with positive tests. RESULTS: We included 56 patients, among whom 46 amoxicillin-suspected were and seven cephalosporin-suspected. Twenty-nine had severe CADR, and 27 had non-immediate maculopapular exanthema (MPE). Twenty-two had positive tests (18 for AS and four for CS). Among the 18 positive amoxicillin-suspected, 10 (55.6%) showed cross-reactivity with one or more other BL: 9 (50%) with another penicillin and 3 (16.5%) with a non-aminocephalosporin. No amoxicillin- or cephalosporin-suspected patient showed cross-reactivity with aztreonam or carbapenems. P-IDR showed cross-reactivity only once. CONCLUSION: After a suspected BL-induced non-immediate CADR, a large allergologic exploration is needed to confirm the diagnosis and evaluate cross-reactivity. In our population including cases of severe CADRs and MPE with late delay of onset, cross-reactivity was frequent and PT was sufficient to this purpose. The frequent cross-reactivity among penicillins encourages stopping this whole family and to test cephalosporins, aztreonam and carbapenems for which cross-allergies are rarer.
引用
- Bérot V, Gener G, Ingen-Housz-Oro S, et al. Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol. 2019. PMID: 31571276. doi:10.1111/jdv.15986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。